bioRxiv · 14 Aug 2026 · Preprint

Protein design to broadly reprogram engineered T cell function

Boyken, Merillat + 18 more

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I.
Cancer Discovery · 9 June 2026 · News
In vivo CAR T-cell therapy KLN-1010 achieved a 100% overall response rate in all 18 multiple myeloma patients in a Phase I trial.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42261652
Open in JClub
First CAR T-Cell Therapy Approved for Solid Tumors.
Cancer Discovery · 21 July 2026 · News
China approves satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors, showing promise in gastric and gastro-esophageal cancers with improved survival metrics.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42478469
Open in JClub
Promises and potential pitfalls of in vivo CAR gene therapy.
Blood · 30 July 2026 · Review
In vivo CAR gene therapy shows promising clinical proof of concept with potential to overcome ex vivo manufacturing limitations.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42172553
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read